Pfizer 2011 Annual Report Download - page 114

Download and view the complete annual report

Please find page 114 of the 2011 Pfizer annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.

Page out of 117

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • 34
  • 35
  • 36
  • 37
  • 38
  • 39
  • 40
  • 41
  • 42
  • 43
  • 44
  • 45
  • 46
  • 47
  • 48
  • 49
  • 50
  • 51
  • 52
  • 53
  • 54
  • 55
  • 56
  • 57
  • 58
  • 59
  • 60
  • 61
  • 62
  • 63
  • 64
  • 65
  • 66
  • 67
  • 68
  • 69
  • 70
  • 71
  • 72
  • 73
  • 74
  • 75
  • 76
  • 77
  • 78
  • 79
  • 80
  • 81
  • 82
  • 83
  • 84
  • 85
  • 86
  • 87
  • 88
  • 89
  • 90
  • 91
  • 92
  • 93
  • 94
  • 95
  • 96
  • 97
  • 98
  • 99
  • 100
  • 101
  • 102
  • 103
  • 104
  • 105
  • 106
  • 107
  • 108
  • 109
  • 110
  • 111
  • 112
  • 113
  • 114
  • 115
  • 116
  • 117

Quarterly Consolidated Financial Data (Unaudited)
Pfizer Inc. and Subsidiary Companies
QUARTER
(MILLIONS OF DOLLARS, EXCEPT PER COMMON SHARE DATA) FIRST SECOND THIRD FOURTH
2011
Revenues $16,502 $ 16,984 $17,193 $ 16,746
Costs and expenses(a) 12,490 12,823 12,423 13,993
Acquisition-related in-process research and development charges ————
Restructuring charges and certain acquisition-related costs(b) 894 479 1,101 460
Income from continuing operations before provision for taxes on income 3,118 3,682 3,669 2,293
Provision for taxes on income 894 1,094 1,235 800
Income from continuing operations 2,224 2,588 2,434 1,493
Discontinued operations—net of tax(c) 10 30 1,315 (43)
Net income before allocation to noncontrolling interests 2,234 2,618 3,749 1,450
Less: Net income attributable to noncontrolling interests 12 8 11 11
Net income attributable to Pfizer Inc. $ 2,222 $ 2,610 $ 3,738 $ 1,439
Earnings per common share—basic:
Income from continuing operations attributable to Pfizer Inc. common
shareholders $ 0.28 $ 0.33 $ 0.31 $ 0.19
Discontinued operations—net of tax — — 0.17 (0.01)
Net income attributable to Pfizer Inc. common shareholders $ 0.28 $ 0.33 $ 0.48 $ 0.19
Earnings per common share—diluted:
Income from continuing operations attributable to Pfizer Inc. common
shareholders $ 0.28 $ 0.33 $ 0.31 $ 0.19
Discontinued operations—net of tax — — 0.17 (0.01)
Net income attributable to Pfizer Inc. common shareholders $ 0.28 $ 0.33 $ 0.48 $ 0.19
Cash dividends paid per common share $ 0.20 $ 0.20 $ 0.20 $ 0.20
Stock prices
High $ 20.57 $ 21.45 $ 20.95 $ 21.90
Low $ 17.62 $ 19.10 $ 16.63 $ 17.05
(a) The fourth quarter of 2011 reflects historically higher Q4 costs in Cost of sales, Selling, informational and administrative expenses, Research and
development expenses and Other deductions—net.
(b) The third quarter of 2011 reflects higher employee termination costs.
(c) The third quarter of 2011 reflects the gain on the sale of Capsugel.
Basic and diluted EPS are computed independently for each of the periods presented. Accordingly, the sum of the quarterly EPS
amounts may not agree to the total for the year.
As of January 31, 2012, there were 223,038 holders of record of our common stock (New York Stock Exchange symbol PFE).
2011 Financial Report 113